AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31048444
Drug: Placebo (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (50 mL) with standard preoperative infusion of normal saline (1.5 L)
Trial: 12118865
Drug: Concurrent auditory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent auditory task
Trial: 7818116
Drug: Intravenous oxycodone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous oxycodone (7.9 +/- 1.5 mg)
Trial: 7818116
Drug: Rectal oxycodone
RxNorm normalized name: oxycodone Rectal Suppository
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal oxycodone (30 mg)
Trial: 23110515
Drug: Insecticide treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insecticide treated materials (ITMs) including PermaNet 2.0 netting treated with deltamethrin at 55 mg/m2 and targeted interventions (larviciding with Temephos, elimination of breeding sites)
Trial: 20507292
Drug: Rituximab therapy
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab therapy (2.0 grams divided into two doses of 1.0 gram on days 1 and 15)
Trial: 20507292
Drug: Methotrexate (not
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (not specified dosage or duration)
Trial: 17143011
Drug: Reference preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference preparation containing fusidic acid
Trial: 16320790
Drug: Progestin‐only injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progestin‐only injectable hormonal contraceptive Norethisterone oenanthate 200 mg
Trial: 11142535
Drug: Virtual Reality
RxNorm normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Virtual Reality Exposure (VRE) therapy
Trial: 11142535
Drug: Standard Exposure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Exposure (SE) therapy
Trial: 358754
Drug: Clomipramine (50-125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine (50-125 mg/day)
Trial: 358754
Drug: Amitriptyline (50-125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (50-125 mg/day)
Trial: 30779375
Drug: fesoterodine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fesoterodine (4 mg/day)
Trial: 30779375
Drug: mirabegron (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mirabegron (50 mg/day)
Trial: 23982939
Drug: CSE‐EVR (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CSE‐EVR (combined spinal-epidural anaesthesia) with 0.5 mg per 10 cm height of hyperbaric levobupivacaine and 20 microg fentanyl, followed by 20 mL saline solution injection
Trial: 21049267
Drug: THC (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC (400 μg/kg)
Trial: 21049267
Drug: Alcohol (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0.5 mg/ml and 0.7 mg/ml)
Trial: 21049267
Drug: Placebo (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0 mg/ml)
Trial: 16256874
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy for ventricular tachycardia (VT) or ventricular fibrillation (VF)
Trial: 10515402
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline (1 mg q.i.d.)
Trial: 10515402
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol (100, 100, 200 microg at 5 min intervals)
Trial: 8787255
Drug: Caudal epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal epidural steroid
Trial: 8787255
Drug: Lumbar epidural
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar epidural steroid
Trial: 1799922
Drug: Quinapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinapril (10 to 20 mg daily)
Trial: 1799922
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 to 20 mg daily)
Trial: 23473338
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (to achieve a hemoglobin target of 13 g per deciliter)
Trial: 21917440
Drug: Inhaled fluticasone
RxNorm normalized name: fluticasone Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled fluticasone propionate 500 μg (FP500) twice-daily
Trial: 15198477
Drug: Probucol (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (500 mg/day, n=9)
Trial: 11028729
Drug: Ropivacaine 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 3.75 mg/ml
Trial: 11028729
Drug: Saline 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 0.3 ml/kg
Trial: 3604970
Drug: Fructo-oligosaccharide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo-oligosaccharide (5 g tid for 12 d)
Trial: 3604970
Drug: Sucrose (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (5 g tid for 12 d)
Trial: 3604970
Drug: Fructo-oligosaccharide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fructo-oligosaccharide (10 g)
Trial: 25201934
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy‐oriented anger management and stress control program (5 sessions, 90 minutes each)
Trial: 25201934
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy‐oriented anger management and stress control program
Trial: 20029974
Drug: Celiac axis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiac axis infusion chemotherapy combined with radiotherapy (CAI/RT)
Trial: 1316401
Drug: Low-sodium diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-sodium diet (LSD) with lactose capsules
Trial: 1316401
Drug: Normal-sodium diet
RxNorm normalized name: sulfacetamide sodium Medicated Pad [Rosula NS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal-sodium diet (NSD) with salt capsules
Trial: 29888656
Drug: Lactobacillus acidophilus
RxNorm normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R and Lactobacillus rhamnosus CLR2, 2 capsules daily containing 50×10^9 cfu of live organisms
Trial: 29888656
Drug: Placebo, 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 2 capsules daily
Trial: 21427425
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (CT, n = 65)
Trial: 9562293
Drug: C (caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C (caffeine 5 mg x kg[-1])
Trial: 9562293
Drug: E (ephedrine
RxNorm normalized name: Primatene (ephedrine hydrochloride 12.5 MG / guaifenesin 200 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E (ephedrine 1 mg x kg[-1])
Trial: 9562293
Drug: C+E (caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C+E (caffeine and ephedrine combination)
Trial: 7936513
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 10 mg/day for 14 days every 28 days
Trial: 7936513
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 10 mg/day for 28 of 84 days
Trial: 7936513
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 10 mg/day for 14 days every 84 days
Trial: 7936513
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (less than monthly)
Trial: 7936513
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate (monthly)
Trial: 2447257
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose phenobarbital treatment (15 mg/kg IV at 110 minutes, followed by 15 mg/kg after 4 hours, then 5 mg/kg every 24 hours for 5 days)
Trial: 2447257
Drug: Early high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early high-dose phenobarbital treatment
Trial: 26337539
Drug: Bi-weekly alternating
RxNorm normalized name: selinexor
DrugBank: Selinexor (DB11942)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bi-weekly alternating ranibizumab/bevacizumab injections
Trial: 21138462
Drug: Testosterone supplementation
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone supplementation (160 mg/day of oral testosterone undecanoate)
Trial: 15760313
Drug: Buscopan suppositories
RxNorm normalized name: Buscopan
DrugBank: Butylscopolamine (DB09300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan suppositories
Trial: 9845395
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (ulcer-like dyspepsia)
Trial: 9845395
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg (ulcer-like dyspepsia)
Trial: 9845395
Drug: Omeprazole 20
RxNorm normalized name: omeprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 20 mg (reflux-like dyspepsia)
Trial: 9845395
Drug: Omeprazole 10
RxNorm normalized name: omeprazole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole 10 mg (reflux-like dyspepsia)
Trial: 7814301
Drug: Nilvadipine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nilvadipine (16 mg daily)
Trial: 29526614
Drug: Elosulfase alfa
RxNorm normalized name: Elosulfase alfa
DrugBank: Elosulfase alfa (DB09051)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Elosulfase alfa 2.0 mg/kg/week
Trial: 15994264
Drug: Cisplatin-based chemotherapy
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin-based chemotherapy + supportive care (C)
Trial: 10093002
Drug: CR2194 (spiroglumide)
RxNorm normalized name: proglumide
DrugBank: Proglumide (DB13431)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR2194 (spiroglumide) 1, 2.5 or 7.5 mg kg‐1 h‐1
Trial: 10093002
Drug: CR2194 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CR2194 (7.5 mg kg‐1 h‐1)
Trial: 8604591
Drug: desferrioxamine B
RxNorm normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desferrioxamine B (100 mg/kg/day) as a single agent
Trial: 8604591
Drug: desferrioxamine B
RxNorm normalized name: Deferrioxamine B
DrugBank: Deferoxamine (DB00746)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: desferrioxamine B in addition to standard quinine-based therapy
Trial: 8604591
Drug: placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo in addition to standard quinine-based therapy
Trial: 22896665
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg BMS‐663068 plus 100 mg ritonavir every 12 hours (Q12H)
Trial: 22896665
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg BMS‐663068 plus 100 mg ritonavir every bedtime
Trial: 22896665
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg BMS‐663068 plus 100 mg ritonavir Q12H
Trial: 22896665
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg BMS‐663068 Q12H plus 100 mg ritonavir every morning
Trial: 22896665
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg BMS‐663068 Q12H
Trial: 12379064
Drug: Ximelagatran, 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran, 24 mg twice daily for 7 to 12 days
Trial: 12379064
Drug: Warfarin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin (target INR 2.5, range 1.8 to 3.0), starting on the evening of the day of surgery
Trial: 9822045
Drug: Moxonidine (0.2-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (0.2- to 0.4-mg)
Trial: 9822045
Drug: Cilazapril (2.5-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (2.5- to 5.0-mg)
Trial: 8017470
Drug: Fluvastatin 20
RxNorm normalized name: fluvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvastatin 20 mg once daily for 6 weeks, then 20 mg twice daily for an additional 6 weeks
Trial: 2637069
Drug: Pentazocin or
RxNorm normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pentazocin or Piritramid (analgesics)
Trial: 334185
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg of aspirin
Trial: 334185
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Trial: 334185
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Trial: 334185
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of 43‐715 (1‐isopropyl‐4‐phenyl-7-methyl-2 (1H) quinazolone)
Trial: 31555976
Drug: Nutraceutical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutraceutical treatment (Omega‐3: EPA 1 g/DHA 656 mg, SAMe, zinc, 5‐HTP, folinic acid, and co‐factors)
Trial: 25705872
Drug: 52 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 52 weeks nicotine patch treatment
Trial: 23518148
Drug: Sunitinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib therapy (2nd-line)
Trial: 21460008
Drug: Pentavalent antimony
RxNorm normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimony treatment with early antihelminthic therapy
Trial: 21460008
Drug: Pentavalent antimony
RxNorm normalized name: Pentavalent Antimony
DrugBank: Pentavalent Antimony (DB13047)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentavalent antimony treatment with deferred antihelminthic therapy
Trial: 16469323
Drug: Oral conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral conjugated equine estrogen (CEE) therapy
Trial: 9182082
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil tablet form (250 mg)
Trial: 9182082
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil granule form (250 mg)
Trial: 2967185
Drug: Bisoprolol 10
RxNorm normalized name: bisoprolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 10 mg o.d. for 4 weeks, then 20 mg o.d. for 4 weeks
Trial: 2967185
Drug: Verapamil 80
RxNorm normalized name: verapamil 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil 80 mg t.i.d. for 4 weeks, then 120 mg t.i.d. for 4 weeks
Trial: 30309721
Drug: IV elesclomol
RxNorm normalized name: Elesclomol
DrugBank: Elesclomol (DB05719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV elesclomol plus weekly paclitaxel
Trial: 24769437
Drug: D-cycloserine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine (50 mg) each treatment day
Trial: 24769437
Drug: Greater distribution
RxNorm normalized name: greater celandine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Greater distribution of treatment (10 weeks)
Trial: 17640375
Drug: Sucrose (44%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucrose (44% sucrose, 2 ml)
Trial: 17640375
Drug: Control (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sterile water, 2 ml)
Trial: 12932114
Drug: Tc-99m DTPA
RxNorm normalized name: TECHNETIUM (Tc 99m)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tc-99m DTPA radioaerosol lung scintigraphy (inhalation of radiotracer for 5 minutes)
Trial: 8664521
Drug: CyA and
RxNorm normalized name: CyA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CyA and steroids (group 1)
Trial: 6401365
Drug: D-penicillamine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-penicillamine therapy for 1 year
Trial: 6401365
Drug: Oral gold
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral gold (Auranofin)
Trial: 31924332
Drug: T +
RxNorm normalized name: RE PreVit + DHA Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T + PLD (trabectedin 1.1 mg/m2 for 3 h; PLD 30 mg/m2 for 1.5 h, every 3 weeks)
Trial: 31924332
Drug: PLD (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD (50 mg/m2 for 1.5 h, every 4 weeks)
Trial: 24880643
Drug: Ivermectin (IVM)
RxNorm normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ivermectin (IVM) at 0.2 mg/kg bodyweight
Trial: 24880643
Drug: Moxidectin (MOX)
DrugBank: Moxidectin (DB11431)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxidectin (MOX) at 0.4 mg/kg bodyweight
Trial: 16358301
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) at a dose of 1,000 mg/m2 given as a 36-hour continuous infusion
Trial: 9521199
Drug: Double therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double therapy (CsA [10 mg/kg/day] plus prednisone)
Trial: 9521199
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (CsA [6 mg/kg/day] plus azathioprine plus prednisone)
Trial: 8004841
Drug: Bisoprolol (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol (all doses combined)
Trial: 788293
Drug: Flutamide (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide (high or low dose)
Trial: 788293
Drug: Diethylstilbestrol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diethylstilbestrol (1 mg daily)
Trial: 29444502
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 1% starch and 10% sucrose
Trial: 23893098
Drug: Project SEARCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Project SEARCH plus ASD Supports (treatment group)
Trial: 22399630
Drug: Carboplatin (AUC5)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5) on day 1 with escalating oral topotecan (3.0 mg/m² starting dose) on days 1, 8, and 15, every 4 weeks
Trial: 22399630
Drug: Carboplatin (AUC5)
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin (AUC5) with oral topotecan
Trial: 20592644
Drug: Therapeutic drug
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic drug monitoring (TDM) for adjusting doses of HIV-1 protease inhibitors (PIs)
Trial: 15913800
Drug: 4-week ribavirin
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-week ribavirin (RIB) administration followed by 24-week combination treatment with interferon (IFN) and RIB (Group A)
Trial: 15913800
Drug: 24-week combination
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24-week combination treatment with interferon (IFN) and ribavirin (RIB) only (Group B)
Trial: 12806908
Drug: Logotherapy (added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Logotherapy (added to loxoprofen sodium treatment)
Trial: 26853244
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy, noise cancelling earplugs, and eye mask
Trial: 17372126
Drug: Risedronate (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate (2.5 mg daily) and vitamin D2 (1,000 IU)
Trial: 6168848
Drug: Mexiletine (600-1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mexiletine (600-1000 mg/day)
Trial: 25388643
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection hyaluronic acid (IAHA) for 4 weeks
Trial: 25388643
Drug: Oral glucosamine
RxNorm normalized name: glucosamine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucosamine sulfate (GS) for 12 weeks